FDA recommended a new survival-confirmatory trial prior to BLA submission, despite statistically significant ORR and PFS ...

New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.

Shubham Pant, MD, MBBS, discusses the rapidly growing pipeline of RAS-directed agents for patients with pancreatic cancer, building on the momentum of the recent FDA approval of daraxonrasib (Rasonque ...

Hans Lee, MD, discusses the importance of BCMA-targeted therapy and the differences between CAR T and bispecific antibody therapy in multiple myeloma.

Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that ...

Bispecific administration is already routine in independent community oncology, with 91.4% of responding practices delivering therapy and 5.4% planning implementation within 12 months. Office-based ...

Geoffrey Y. Ku, MD discusses two of the most active areas of investigation in the perioperative management of gastric and gastroesophageal junction (GEJ) cancers targeting HER2-positive disease and ...

Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings. The 23rd International Myeloma Society ...

The imlunestrant label includes a warning and precaution for embryo-fetal toxicity, and the abemaciclib label includes ...

CAR T and bispecific T-cell engagers move earlier in blood cancer care, reshaping sequencing and expanding access beyond academic centers. T-cell–based immunotherapies have transformed the treatment ...

Martin Dietrich, MD, PhD, says he manages neurologic adverse events reactively rather than proactively, because he cannot predict who will develop them and because on-target effects tend to appear ...

Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care. Chronic lymphocytic leukemia (CLL) treatment has undergone ...